Tumor microenvironment classification based on T‑cell infiltration and PD‑L1 in patients with mismatch repair‑proficient and ‑deficient colorectal cancer

Liu,Shousheng; Kong,Pengfei; Wang,Xiaopai; Yang,Lin; Jiang,Chang; He,Wenzhuo; Quan,Qi; Huang,Jinsheng; Xie,Qiankun; Xia,Xiaojun; Zhang,Bei; Xia,Liangping

doi:10.3892/ol.2018.9826

Tumor microenvironment classification based on T‑cell infiltration and PD‑L1 in patients with mismatch repair‑proficient and ‑deficient colorectal cancer

Authors:
- Shousheng Liu
- Pengfei Kong
- Xiaopai Wang
- Lin Yang
- Chang Jiang
- Wenzhuo He
- Qi Quan
- Jinsheng Huang
- Qiankun Xie
- Xiaojun Xia
- Bei Zhang
- Liangping Xia
View Affiliations

Affiliations: State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat‑Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China, Department of Pathology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510080, P.R. China
Published online on: December 12, 2018 https://doi.org/10.3892/ol.2018.9826
Pages: 2335-2343
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The classification of tumor microenvironments according to the presence or absence of tumor infiltrating lymphocytes (TILs) and programmed death ligand‑1 (PD‑L1) expression has been used to predict the efficacy of immune checkpoint inhibitor antibodies in several cancer types, not including colorectal cancer (CRC). The current study investigated the TIL/PD‑L1 status of patients with CRC, particularly patients who presented as mismatch repair‑proficient (pMMR) and mismatch repair‑deficient (dMMR). A total of 243 patients with CRC were enrolled and defined as pMMR (121 patients) or dMMR (122 patients). Using Pearson's χ2 test and multivariable multinomial logistic regression analysis, the associations between MMR status, TIL presence and PD‑L1 expression were investigated, in addition to the association between TIL/PD‑L1 status and clinicopathological features. The results demonstrated that the dMMR group more frequently exhibited TIL+ (85/122 vs. 61/121) and PD‑L1+ (49/122 vs. 32/121) phenotypes compared with the pMMR group. PD‑L1+ expression was identified in 42.4% of TIL+ cases in the dMMR group, while only 18.0% of TIL+ cases were PD‑L1+ in the pMMR group. High programmed death‑1 expression and dMMR status were revealed as two independent risk factors for TIL+ PD‑L1+ status. In conclusion, compared with the pMMR group, the dMMR group was more likely to present with a TIL+ PD‑L1+ status, which suggests that a TIL+ PD‑L1+ tumor microenvironment may partly contribute to the improved response of dMMR patients to anti‑PD‑1/L1 therapy.

View Figures

View References

1	Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
2	Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
3	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
4	Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014. View Article : Google Scholar : PubMed/NCBI
5	Lin WF, Lu JY, Cheng BB and Ling CQ: Progress in research on the effects of traditional Chinese medicine on the tumor microenvironment. J Integr Med. 15:282–287. 2017. View Article : Google Scholar : PubMed/NCBI
6	Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL and Chen L: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 4:127ra372012. View Article : Google Scholar : PubMed/NCBI
7	Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI
8	Kalbasi A, June CH, Haas N and Vapiwala N: Radiation and immunotherapy: A synergistic combination. J Clin Invest. 123:2756–2763. 2013. View Article : Google Scholar : PubMed/NCBI
9	Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, et al: CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 17:4101–4109. 2011. View Article : Google Scholar : PubMed/NCBI
10	Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
11	Teng MW, Ngiow SF, Ribas A and Smyth MJ: Classifying cancers based on t-cell infiltration and PD-L1. Cancer Res. 75:2139–2145. 2015. View Article : Google Scholar : PubMed/NCBI
12	Klintrup K, Mäkinen JM, Kauppila S, Väre PO, Melkko J, Tuominen H, Tuppurainen K, Mäkelä J, Karttunen TJ and Mäkinen MJ: Inflammation and prognosis in colorectal cancer. Eur J Cancer. 41:2645–2654. 2005. View Article : Google Scholar : PubMed/NCBI
13	Shen SJ, Zhang YH, Gu XX, Jiang SJ and Xu LJ: Yangfei Kongliu Formula, a compound Chinese herbal medicine, combined with cisplatin, inhibits growth of lung cancer cells through transforming growth factor-β1 signaling pathway. J Integr Med. 15:242–251. 2017. View Article : Google Scholar : PubMed/NCBI
14	Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, et al: Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer. 49:2233–2242. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Sun Z, Mao X, Wu H, Luo F, Wu X, Zhou L, Qin J, Zhao L and Bai C: Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment. Oncotarget. 8:85526–85536. 2017.PubMed/NCBI
16	Park JH, Powell AG, Roxburgh CS, Horgan PG, McMillan DC and Edwards J: Mismatch repair status in patients with primary operable colorectal cancer: Associations with the local and systemic tumour environment. Br J Cancer. 114:562–570. 2016. View Article : Google Scholar : PubMed/NCBI
17	Smyrk TC, Watson P, Kaul K and Lynch HT: Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 91:2417–2422. 2001. View Article : Google Scholar : PubMed/NCBI
18	Inaguma S, Lasota J, Felisiak-Golabek A, Kowalik A, Wang Z, Zieba S, Kalisz J, Ikeda H and Miettinen M: Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274)-expression: Possible roles of tumour micro environmental factors for CD274 expression. J Pathol Clin Res. 3:268–278. 2017. View Article : Google Scholar : PubMed/NCBI
19	Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG and Mino-Kenudson M: PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol. 29:1104–1112. 2016. View Article : Google Scholar : PubMed/NCBI
20	Chen DS, Irving BA and Hodi FS: Molecular pathways: Next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 18:6580–6587. 2012. View Article : Google Scholar : PubMed/NCBI
21	Woerner SM, Gebert J, Yuan YP, Sutter C, Ridder R, Bork P and von Knebel Doeberitz M: Systematic identification of genes with coding microsatellites mutated in DNA mismatch repair-deficient cancer cells. Int J Cancer. 93:12–19. 2001. View Article : Google Scholar : PubMed/NCBI
22	Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik B, Galon J and Trajanoski Z: Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 16:642015. View Article : Google Scholar : PubMed/NCBI
23	Dong H, Zhu G, Tamada K and Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999. View Article : Google Scholar : PubMed/NCBI
24	Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
25	Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, Shalabi A, Shin T, Pardoll DM and Tsuchiya H: B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med. 193:839–846. 2001. View Article : Google Scholar : PubMed/NCBI
26	Sznol M and Chen L: Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 19:1021–1034. 2013. View Article : Google Scholar : PubMed/NCBI
27	Aboudaram A, Modesto A, Chaltiel L, Gomez-Roca C, Boulinguez S, Sibaud V, Delord JP, Chira C, Delannes M, Moyal E and Meyer N: Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: A safe and effective combination. Melanoma Res. 27:485–491. 2017. View Article : Google Scholar : PubMed/NCBI
28	Karaca B, Yayla G, Erdem M and Gürler T: Electrochemotherapy with anti-PD-1 treatment induced durable complete response in heavily pretreated metastatic melanoma patient. Anticancer Drugs. Dec 21–2017.(Epub ahead of print). doi: 10.1097/CAD.0000000000000580. View Article : Google Scholar